Drug Database
CL

clotrimazole + betamethasone (Flotiran / Lotrisone / Lotricomb)

✓ Approved

Merck & Co. · NR3C1 · 小分子

什么是 clotrimazole + betamethasone?

clotrimazole + betamethasone 是一种小分子,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名Flotiran, Lotrisone, Lotricomb
公司Merck & Co.
药物类别小分子
分子靶点NR3C1,
给药途径Unknown
状态Approved

作用机制

分子靶点

clotrimazole + betamethasone 作用于 2 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
sterol demethylase, Candida albicans (ERG11)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

clotrimazole + betamethasone 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsWound infection fungal✓ Approved

相关研究文献

PubMedVestnik otorinolaringologii2026-11-18

[Possibilities of topical therapy of acute bullous otitis media].

Baranov K K KK, Vyazmenov E O EO, Kotova E N EN, Polunin M M MM et al.

Bullous myringitis is a borderline condition between inflammatory processes of the external and middle ear. The aim was to evaluate the comparative efficacy of three combined topical preparations in complex treatment of acute bullous otitis media. 140 patients aged 6-40 years (110 (78.6%) children) were divided into three groups: group 1 (n=50) - chloramphenicol+clotrimazole+beclomethasone dipropionate+lidocaine hydrochloride; group 2 (n=45) - phenazone+lidocaine; group 3 (n=45) - neomycin+polymyxin B+dexamethasone. Pain relief was fastest in group 2 (by day 3); otoscopic signs resolved by day 5, with the best combined results in group 1. In 25-28 (17.9-20.0%) patients bullous otitis was associated with PCR-confirmed influenza A (H1N1); Mycoplasma pneumoniae was detected in 4 (2.9%). The incidence peaked in December-February.

PMID 43046736
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Evaluation of Individualized Sequential Therapy Centered on Surgical Excision and Superficial Radiotherapy in Treating Keloids in the Anterior Chest Wall.

Zou Ming-Li ML, Shen Fang-Cheng FC, Wang Qian Q, Jiang Zi-Yu ZY et al.

This study aims to evaluate the efficacy of individualized sequential therapy centered on surgical excision and superficial radiotherapy for the treatment of sternal keloids. This study retrospectively analyzed the clinical data of 42 patients with sternal keloids admitted to a tertiary hospital in eastern China between January 2022 and December 2024. All patients received an individualized sequential therapy. Preoperatively, surgical approaches were selected based on the size and morphology of the keloids, including direct excision with tension-reduction sutures, flap reconstruction following excision, punch excision, and a combination of surgical excision and punch excision. Postoperative sequential adjuvant therapies included superficial radiotherapy, topical anti-scarring medications and dressings, and regular fractional laser treatment combined with compound betamethasone importation, sustained for 6 months. The Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS) were used to evaluate scar improvement and clinical efficacy before treatment and at 12 months postoperatively. The response rate, recurrence rate, adverse reactions, and long-term outcomes were statistically analyzed. At 1 year postoperatively, VSS, OSAS, and PSAS scores decreased across all four subgroups compared with baseline. Significant differences between pre- and post-treatment scores were observed in the tension-reducing suture repair group (n = 18), IMAP flap reconstruction group (n = 9), and punch excision therapy group (n = 10) (all p < 0.05). The combined excision group (n = 5) showed a downward trend in postoperative scores, but the difference did not reach statistical significance (p = 0.063). The overall response rate was 88.1%. Postoperative radiation dermatitis occurred in 3 cases, which healed well after symptomatic management. During the follow-up period, recurrence was observed in 5 patients (11.9%), whose symptoms were alleviated following local injections of compound betamethasone. At the end of the follow-up period ranging from 12 to 24 months (mean: 19 months), all patients maintained stable or improved scar conditions, indicating favorable long-term efficacy. Individualized sequential therapy centered on surgical excision and superficial radiotherapy, combined with other long-term adjuvant treatments, demonstrates superior efficacy in the treatment of sternal keloids and is recommended for clinical application.

PMID 43047184
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

A Sequential Treatment of Keloids: Multiple-Hole Punch Excision Combined With Superficial Radiation and Drug.

Gong Zhicheng Z, Jing Wenwen W, Zhang Zhenhua Z, Rao Wenbin W et al.

Dense and multiple keloids present significant therapeutic challenges due to their stubborn nature and high recurrence rates. Although various treatment options exist, optimizing current approaches and integrating them into a rational, systematic regimen for keloid management remains a difficult clinical problem. This study aims to establish an effective multimodal sequential treatment protocol for patients with dense, multiple keloids. A total of 87 patients with 285 keloid lesions were enrolled from September 2023 to April 2024. All cases underwent a sequential treatment: Stage I involved drug-assisted multiple-hole punch excision followed by adjuvant superficial radiotherapy; Stage II consisted of periodic intralesional injections of betamethasone and 5-fluorouracil. Clinical outcomes, recurrence, and adverse events were evaluated at 12-month follow-up. The POSAS and VSS scores were recorded at each time point. At 12 months post-treatment, marked improvement was achieved in 78 patients (89.66%), with improvement in 7 (8.04%) and ineffective results in 2 (2.30%). The POSAS and VSS scores were recorded before treatment and at follow-up points at 30, 60, 90, 180, and 360 days. All patients developed varying degrees of local hyperpigmentation within 2 months after Stage I of multi-hole punch excision. In 80.75% of cases, the hyperpigmentation resolved within 3 months following Stage I, with the longest duration of resolution being 12 months. During Stage I, four cases of localized ulcers and five instances of acute radiation dermatitis appeared. All adverse reactions were effectively alleviated. No other adverse reactions occurred. This sequential treatment protocol offers a practical, minimally invasive, and effective option for patients with multiple, dense keloids.

PMID 43047096
阅读全文 →
PubMedPolymers2026-11-14

Biaxial Electrospinning of Poly(lactic acid)/Poly(butylene adipate-co-terephthalate) Blend and Polyvinylpyrrolidone Membranes for Topical Delivery of Betamethasone Valerate.

Schons Édina Liara ÉL, Salamanca Diogo José DJ, Fraga Gabriel Nardi GN, Dragunski Douglas Cardoso DC et al.

Psoriasis is one of the most common skin diseases in the world, and its treatment results in an improvement in the quality of life of patients, carried out mainly with the use of topical corticosteroids such as ointments and gels. As an alternative to conventional treatment of psoriasis, this work presents a study on the production and characterization of polymeric membranes containing betamethasone valerate produced by biaxial electrospinning. PVP has high solubility in water, resulting in rapid release of the incorporated drug. ECOVIO® (BASF, Ludwigshafen, Germany), composed of PLA and PBAT polymers, has good mechanical properties and forms membranes with controlled drug release, due to its hydrophobic characteristics. The produced membranes were characterized by SEM, FTIR, TGA, DSC and XRD. It was demonstrated that the selected polymers presented adequate conditions of electrospinning for membranes prepared in biaxial mode. Characterization showed a possible compatibility between the drug incorporated in the amorphous state and polymers, which also showed increased thermal stability. An increase in the availability of betamethasone valerate incorporated into the membranes (95%) in relation to the isolated active ingredient (20%) was observed in 24 h. Thus, according to the results obtained, the produced membrane is promising for the controlled release of betamethasone valerate.

PMID 43030012
阅读全文 →
PubMedCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique2026-11-14

Combined excision and radiation therapy for keloid management: A systematic review.

Laiman Vincent V, Kurniawan Torana T, Ekaputra Ericko E, Meidania Lidya L et al.

Keloids are fibroproliferative disorders that pose therapeutic challenges due to their high recurrence rates, pain, and discomfort. However, the efficacy between different therapeutic modalities, particularly radiation therapy remains unclear. This systematic review aimed to compare the combination of excision and radiation therapy with other modalities. A systematic literature search from PubMed, Cochrane, and Web of Science was performed in December 2024. Search strategies with keywords related to "keloid", "radiation therapy", "treatment", and "outcome" were performed. Search was limited to prospective clinical trials that compared excision combined with radiation therapy to other keloid treatment modalities. A total of 723 studies were screened and six were included which reported 375 patients with a total of 427 lesions. Radiation therapy doses ranged from 0.8 Gy to 18 Gy, with fractions ranging from one to four. Postoperative irradiation was delivered on the same day or within 48 hours postoperatively. Excision combined with radiation therapy demonstrated higher complete response rates and better pain resolution compared to cryotherapy with triamcinolone acetonide, cryotherapy alone, and betamethasone with 5-fluorouracil, with or without excision. Hyperpigmentation was more commonly reported with excision and radiation therapy, while hypopigmentation was more frequent with other treatments. Studies with patient satisfaction data reported higher satisfaction after combination of excision and radiation therapy compared to other modalities. Excision combined with radiation therapy showed superior outcome compared to other modalities, particularly cryotherapy-based treatment, with higher pain resolution, and patient satisfaction. Notably, brachytherapy yielded the most favorable results in keloid treatment, with earlier postoperative irradiation suggestive of better control.

PMID 43025272
阅读全文 →
PubMedMini reviews in medicinal chemistry2026-11-13

Pharmacological Significance of Imidazole-coumarin Hybrids: Current Perspectives.

Bhyan Puneet P, Rohilla Sonia S, Verma Vikas V, Singh Vikramjeet V et al.

Imidazole and coumarin are privileged heterocyclic scaffolds with broad pharmacological relevance and established clinical applications, exemplified by imidazole-based antifungals such as Miconazole, Clotrimazole, and Ketoconazole, and the coumarin-derived anticoagulant warfarin. Their complementary pharmacophoric features have stimulated the development of imidazolecoumarin hybrids as multifunctional candidates with potentially improved biological profiles. This review critically summarizes recent advances in the synthesis, biological evaluation, Structure- Activity Relationships (SAR), and mechanisms of imidazole-coumarin hybrids. Reported synthetic approaches for these hybrids are briefly outlined, while emphasis is placed on their antibacterial, antifungal, anticancer, antiviral, antioxidant, antitubercular, and antihelminthic activities. Particular attention is given to the influence of substituent type and position on the coumarin and imidazole/ benzimidazole nuclei, as well as linker characteristics, on biological activity. The review further distinguishes experimentally supported molecular mechanisms, including enzyme or target interactions, membrane-related effects, oxidative stress modulation, and apoptosis-associated pathways, from activities established only by phenotypic screening. Available potency data, including MIC and IC50 values, are critically compared where reported, while limited selectivity and ADMET information is highlighted as an important research gap. Finally, current challenges in mechanistic validation, in vivo efficacy, toxicity assessment, and rational SAR-guided optimization are discussed, providing directions for the development of more potent, selective, and pharmacokinetically suitable imidazole-coumarin hybrids.

PMID 43023505
阅读全文 →

注册免费账户还可查看另外 9122 篇文献

免费注册查看全部文献 →

了解更多clotrimazole + betamethasone